More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.
Scientific
coordination
European Foundation for the Study of Chronic Liver Failure (EFCLIF)
Prof. Dr. Rajiv Jalan
Travessera de Gràcia 11, 7th floor
08021 Barcelona, Spain
Prof. Dr. Rajiv Jalan
Travessera de Gràcia 11, 7th floor
08021 Barcelona, Spain
Principal
Investigator
Charité – Universitätsmedizin Berlin (CHARITÉ)
Dr. med. Cornelius Engelmann
Augustenburger Platz 1
13353 Berlin, Germany
Dr. med. Cornelius Engelmann
Augustenburger Platz 1
13353 Berlin, Germany
Project
management
concentris research management GmbH
Fürstenfeldbruck, Germany
Phone: +49 8141 6252 8570
Email: info@atango.eu
Fürstenfeldbruck, Germany
Phone: +49 8141 6252 8570
Email: info@atango.eu
Project partners
